# Te‐Chun Hsia

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/te-chun-hsia/

## Facts

| Field | Value |
| --- | --- |
| Citations | 7,498 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 29 |
| i10-index | 85 |
| Last Known Institution | China Medical University |
| OpenAlex ID | https://openalex.org/A5074784103 |
| ORCID iD | 0000-0003-4297-9918 |
| Works | 294 |

## Researcher papers

- [Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-plus-platinum-etoposide-versus-platinum-etoposide-in-first-line/)
- [Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-with-or-without-tremelimumab-plus-platinum-etoposide-versus-platinum/)
- [Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/ramucirumab-plus-erlotinib-in-patients-with-untreated-egfr-mutated-advanced-non/)
- [Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study](https://scholariq.org/papers/durvalumab-as-third-line-or-later-treatment-for-advanced-non-small-cell-lung/)
- [Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study](https://scholariq.org/papers/pembrolizumab-plus-ipilimumab-or-placebo-for-metastatic-non-small-cell-lung/)
- [Gallic Acid Induces Apoptosis via Caspase-3 and Mitochondrion-Dependent Pathways in Vitro and Suppresses Lung Xenograft Tumor Growth in Vivo](https://scholariq.org/papers/gallic-acid-induces-apoptosis-via-caspase-3-and-mitochondrion-dependent-pathways/)
- [Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study](https://scholariq.org/papers/low-dose-ct-screening-among-never-smokers-with-or-without-a-family-history-of/)
- [Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer](https://scholariq.org/papers/phase-iii-keynote-789-study-of-pemetrexed-and-platinum-with-or-without/)
- [Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial](https://scholariq.org/papers/efficacy-of-aumolertinib-hs-10296-in-patients-with-advanced-egfr-t790m-nsclc/)
- [Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double-blind, cross-over trial.](https://scholariq.org/papers/treatment-of-irritable-bowel-syndrome-with-lacteol-fort-a-randomized-double/)
- [The Feasibility of Interventional Pulmonology Methods for Detecting the T790M Mutation after the First or Second-Generation EGFR-TKI Resistance of Non-Small Cell Lung Cancer](https://scholariq.org/papers/the-feasibility-of-interventional-pulmonology-methods-for-detecting-the-t790m/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Radiomics and Machine Learning in Medical Imaging](https://scholariq.org/topics/radiomics-and-machine-learning-in-medical-imaging/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)

## Researcher university

- [China Medical University](https://scholariq.org/institutions/china-medical-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.